Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.
SNY Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Sanofi with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Sanofi ranked in the 51th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 22.83% on a DCF basis. The most interesting components of our discounted cash flow analysis for Sanofi ended up being:
In the past 4.99 years, Sanofi has a compound free cash flow growth rate of 0.02%; that's higher than merely 21.74% of free cash flow generating stocks in the Healthcare sector.
Sanofi's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 8.41% of tickers in our DCF set.
SNY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than only 8.41% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
DYNT, HRC, LH, CBPO, and ENSG can be thought of as valuation peers to SNY, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
The European Medicines Agency ((EMA)) accepts for review Sanofi's (SNY) marketing application seeking approval of enzyme replacement therapy avalglucosidase alfa for the treatment of Pompe disease, a rare inherited disorder characterized by the buildup of a sugar called glycogen in the body's cells due to the absence of key enzyme...
The European Medicines Agency ((EMA)) has accepted for review Sanofi's (SNY) marketing authorization application for avalglucosidase alfa, for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid α-glucosidase deficiency). Pompe disease is a rare, degenerative muscle disorder that can impact an individual’s ability to move and...
The research study covers the current scenario and growth prospects of the Insulin API market (2020-2025) according to the analysis . This study includes a extensive analysis of the key segments of the industry and also the regional analysis
The latest updated report on the Global Insulin Market added by Reports and Data presents a comprehensive analysis of the industry size, revenue forecast, regional spectrum of the business vertical, and further elaborates on the major hurdles, challenges, and latest
DUBLIN , Oct. 2, 2020 /PRNewswire/ -- The "Worldwide Diabetes Reusable Insulin Delivery Pen Market: Demand, Insights, Trends, Analysis, Opportunities, Growth Potential and Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The Worldwide Diabetes Reusable Insulin Delivery Pen Market size is expected to touch US$ 6 billion by 2026. The report offers the most up-to-date industry data on the actual market situation and future outlook for the worldwide diabetes reusable insulin delivery pen market. The report provides historical market data for 2013 - 2019, and forecasts from 2020 until 2026. The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, reusable insulin pen volume, revenues for reusable...